Edition:
United States

Biofrontera AG (B8FGn.F)

B8FGn.F on Frankfurt Stock Exchange

3.63EUR
10:52am EDT
Change (% chg)

€0.03 (+0.81%)
Prev Close
€3.60
Open
€3.57
Day's High
€3.69
Day's Low
€3.57
Volume
4,835
Avg. Vol
17,329
52-wk High
€4.87
52-wk Low
€2.78

B8FGn.F

Chart for B8FGn.F

About

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and... (more)

Overall

Beta: 0.08
Market Cap(Mil.): €140.60
Shares Outstanding(Mil.): 38.42
Dividend: --
Yield (%): --

Financials

  B8FGn.F Industry Sector
P/E (TTM): -- 213.75 15.85
EPS (TTM): -0.42 -- --
ROI: -116.04 -7.93 -8.31
ROE: -234.75 -9.29 -7.95

BRIEF-Biofrontera files label extension for Ameluz in EU

* FILES LABEL EXTENSION FOR AMELUZ IN EU TO INCLUDE TREATMENT WITH DAYLIGHT-PDT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 12 2017

BRIEF-Biofrontera enters into finance contract with European Investmentbank

* BIOFRONTERA ENTERS INTO FINANCE CONTRACT WITH EUROPEAN INVESTMENTBANK

May 19 2017

BRIEF-Biofrontera Q1 net loss at 3.5 million euros

* SALES INCREASED C. 160% TO EUR2.6 MILLION FOR Q1 2017, COMPARED TO EUR1.0 MILLION IN SAME PERIOD 2016.

May 19 2017

BRIEF-Biofrontera FY sales up 48 pct at 6.1 million euros

* Sales increased 48 pct to 6.1 million euros ($6.47 million) for full year 2016 compared to 4.1 million euros in 2015

Apr 12 2017

BRIEF-Biofrontera: positive prelim results for primary endpoint of Phase III clinical trial (Ameluz)

* Reported on Monday it receives positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of its topical drug BF-200 ALA (Ameluz) in combination with daylight photodynamic therapy (PDT)

Feb 07 2017

BRIEF-Biofrontera: European Commission extends Ameluz approval to basal cell carcinoma

* European Commission extends Ameluz approval to basal cell carcinoma Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 30 2017

Earnings vs. Estimates